Viridian Therapeutics, Inc. (NASDAQ:VRDN) Receives $36.70 Consensus PT from Analysts
Shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN – Get Free Report) have earned a consensus recommendation of “Moderate Buy” from the eleven brokerages that are currently covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a hold rating and ten have given a buy rating to the company. The average […]
Shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN – Get Free Report) have earned a consensus recommendation of “Moderate Buy” from the eleven brokerages that are currently covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a hold rating and ten have given a buy rating to the company. The average […]
